Earlier this week, British drugmaker GSK received approval in Canada for its RSV vaccine for adults aged between 50 and 59 ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

When I first brought my newborn baby home from the hospital at the onset of RSV season, I kept my 2.5-year-old masked for so ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults ...

RSV vaccination for infants and mothers should be administered either in the hospital or directly from a primary health-care ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Pediatric RSV off-season outbreaks and positivity rates increased in China during the COVID-19 pandemic, according to study findings.